Renalytix AI PLC Update on non-executive director appointment (0454O)
30 September 2019 - 5:00PM
UK Regulatory
TIDMRENX
RNS Number : 0454O
Renalytix AI PLC
30 September 2019
Renalytix AI plc
("RenalytixAI" or the "Company")
Update on non-executive director appointment
Renalytix AI plc (AIM: RENX), a developer of artificial
intelligence enabled clinical diagnostics for kidney disease,
announces that it expects to appoint an additional non-executive
director and healthcare industry veteran within the coming
weeks.
A qualified candidate has been identified to the Company and the
process of completing regulatory due diligence is nearing
completion. Further announcements will be made at the appropriate
time.
For further information, please contact:
Renalytix AI plc www.renalytixai.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker) Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison
N+1 Singer (Joint Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
About Kidney Disease
Kidney disease is now recognised as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control estimates there that 15% of United States adults or 37
million people currently have chronic kidney disease. It is
reported that 9 out of 10 adults with CKD do not know they have it
and 1 out of 2 people with very low kidney function who are not on
dialysis do not know they have CKD*. Kidney disease is referred to
as a "silent killer" because it often has no symptoms and can go
undetected until a very advanced stage. Each year kidney disease
kills more people than breast and prostate cancer. Every day 13
patients die in the United States while waiting for a kidney
transplant.
*
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally. The
Company's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery.
For more information, visit renalytixai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDLLMRTMBJTBAL
(END) Dow Jones Newswires
September 30, 2019 03:00 ET (07:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024